{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:28:28Z","timestamp":1786512508227,"version":"build-2736575974"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mucous membrane pemphigoid (MMP) is a mucosal-predominant, potentially scarring autoimmune subepithelial blistering disease. Although dupilumab is approved for adult bullous pemphigoid, its use in MMP remains off-label and published experience is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a 77-year-old man with refractory mucous membrane pemphigoid presenting with recurrent painful oral erosions, ocular symptoms, suspected nasopharyngeal\/upper-airway involvement, and widespread cutaneous blisters. Histopathology showed a subepidermal blister, and direct immunofluorescence revealed linear C3 and IgG deposition along the basement membrane zone; BP180 and BP230 antibodies were elevated. Despite long-term systemic glucocorticoids, disease activity persisted, with chronic obstructive pulmonary disease, prior prostate cancer, and 7.5-kg acute weight loss. Dupilumab was initiated with scheduled prednisone tapering. Pruritus and new blister formation rapidly decreased, erosions re-epithelialized, and oral symptoms, ocular dryness, and tearing improved, prednisone was discontinued after 3\u202fmonths, and dupilumab monotherapy maintained remission without serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights dupilumab-mediated IL-4\/IL-13 blockade as a potential steroid-sparing strategy for carefully selected patients with refractory multisite MMP in whom conventional broad immunosuppression carries substantial risk, while emphasizing that control of active inflammation may not reverse established cicatricial damage and that longer-term controlled studies are needed to confirm its efficacy, durability, and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1915046","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:45:30Z","timestamp":1786509930000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dupilumab enables glucocorticoid withdrawal in refractory multisite mucous membrane pemphigoid: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuan","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Suining Central Hospital","place":["Suining, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu-Li","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Suining Central Hospital","place":["Suining, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Han","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Suining Central Hospital","place":["Suining, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Shui","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Suining Central Hospital","place":["Suining, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Bo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Suining Central Hospital","place":["Suining, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"103036","DOI":"10.1016\/j.autrev.2022.103036","article-title":"Mucous membrane pemphigoid","volume":"21","author":"Du","year":"2022","journal-title":"Autoimmun Rev"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1111\/jdv.17397","article-title":"European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European academy of dermatology and venereology - part I","volume":"35","author":"Rashid","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/jdv.17395","article-title":"European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European academy of dermatology and venereology - part II","volume":"35","author":"Schmidt","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fimmu.2019.00034","article-title":"The diagnosis and blistering mechanisms of mucous membrane pemphigoid","volume":"10","author":"Kamaguchi","year":"2019","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40265-026-02292-3","article-title":"Autoimmune bullous diseases: therapeutic update","volume":"86","author":"Kasperkiewicz","year":"2026","journal-title":"Drugs"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European academy of dermatology and venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/jamadermatol.2021.1036","article-title":"Assessment of diagnostic strategy for mucous membrane pemphigoid","volume":"157","author":"Rashid","year":"2021","journal-title":"JAMA Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1494294","DOI":"10.3389\/fimmu.2024.1494294","article-title":"Bullous pemphigoid and mucous membrane pemphigoid humoral responses differ in reactivity towards BP180 midportion and BP230","volume":"15","author":"Mariotti","year":"2024","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamadermatol.2013.1434","article-title":"Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid","volume":"149","author":"Bernard","year":"2013","journal-title":"JAMA Dermatol"},{"key":"ref11","volume-title":"DUPIXENT (Dupilumab) Injection, for Subcutaneous Use: Prescribing Information","year":"2025"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jdcr.2021.02.010","article-title":"Successful treatment of Brunsting-Perry pemphigoid with dupilumab","volume":"10","author":"Blum","year":"2021","journal-title":"JAAD Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.36849\/JDD.6032","article-title":"Successful treatment of Brunsting-Perry cicatricial pemphigoid with dupilumab","volume":"20","author":"Raef","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"adv40162","DOI":"10.2340\/actadv.v104.40162","article-title":"Successful treatment of mucous membrane pemphigoid with dupilumab: a case report","volume":"104","author":"Wang","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"754","DOI":"10.23736\/S0392-0488.18.06167-9","article-title":"Detection of IgE autoantibodies in mucous membrane pemphigoid and their association with disease severity","volume":"155","author":"Corti","year":"2020","journal-title":"G Ital Dermatol Venereol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/j.1365-2133.2011.10481.x","article-title":"Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis","volume":"165","author":"Yayli","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.2353\/ajpath.2009.090579","article-title":"Conjunctival interleukin-13 expression in mucous membrane pemphigoid and functional effects of interleukin-13 on conjunctival fibroblasts in vitro","volume":"175","author":"Saw","year":"2009","journal-title":"Am J Pathol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e13190","DOI":"10.1111\/dth.13190","article-title":"Targeting interleukin 4 receptor alpha: a new approach to the treatment of cutaneous autoimmune bullous diseases?","volume":"33","author":"Russo","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"101528","DOI":"10.1016\/j.ajoc.2022.101528","article-title":"Dupilumab-associated cicatrizing ocular disease","volume":"26","author":"Reddy","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1007\/s12325-024-02810-3","article-title":"Study design of a phase 2\/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT","volume":"41","author":"Murrell","year":"2024","journal-title":"Adv Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1915046\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:45:40Z","timestamp":1786509940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1915046\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":20,"alternative-id":["10.3389\/fmed.2026.1915046"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1915046","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1915046"}}